Literature DB >> 15310938

Substance use of disorders in HIV-infected patients: impact and new treatment strategies.

David A Fiellin1.   

Abstract

Substance use of disorders--including alcohol, cocaine, and opiod dependencies--are common in HIV-infected patients. Untreated substance use disorders result in poor HIV disease treatment outcomes; however, several new treatment strategies have emerged in recent years. Combined medication and counseling therapies are effective for alcohol and opioid dependencies, and counseling treatments are effective for cocaine dependence. Office-based treatment with buprenorphine offers the opportunity for coordinated treatment of HIV disease and opioid dependence. This article summarizes a presentation by David A. Fiellin, MD, in March 2004 at the International AIDS Society-USA New York course.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310938

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  6 in total

1.  What can mental health interventions contribute to the global struggle against HIV/AIDS?

Authors:  Francine Cournos; Karen McKinnon; Milton Wainberg
Journal:  World Psychiatry       Date:  2005-10       Impact factor: 49.548

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

3.  Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care.

Authors:  P Todd Korthuis; Jessica Gregg; Wendy E Rogers; Dennis McCarty; Christina Nicolaidis; Joshua Boverman
Journal:  J Addict Med       Date:  2010-12       Impact factor: 3.702

4.  Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.

Authors:  P Todd Korthuis; David A Fiellin; Rongwei Fu; Paula J Lum; Frederick L Altice; Nancy Sohler; Mary J Tozzi; Steven M Asch; Michael Botsko; Margaret Fishl; Timothy P Flanigan; Joshua Boverman; Dennis McCarty
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

5.  Measuring alcohol consumption using Timeline Followback in non-treatment-seeking medical clinic patients with and without HIV infection: 7-, 14-, or 30-day recall.

Authors:  David A Fiellin; Kathleen A McGinnis; Stephen A Maisto; Amy C Justice; Kendall Bryant
Journal:  J Stud Alcohol Drugs       Date:  2013-05       Impact factor: 2.582

6.  Integrating substance abuse treatment into HIV care: missed opportunities in the AIDS Drug Assistance Program.

Authors:  Erika G Martin; Karen H Wang
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.